Browse Menu >>

Browse Subjects >>

Biomedical & Life Sciences

Business & Economics

Chemistry & Materials Science

Computer Science & Communications

Earth & Environmental Sciences

Engineering

Medicine & Healthcare

Physics & Mathematics

Social Sciences & Humanities

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

C. Borghi and A. F. G. Cicero, “Blood Pressure Modulating Properties of Omega-3 Polyunsaturated Fatty Acids(PUFA). Another PUFA Heart Protective Effect?” High Blood Pressure and Cardiovascular Prevention, Vol. 14, No. 2, 2007, pp. 1-7. doi:10.2165/00151642-200714020-00001

has been cited by the following article:

  • TITLE: Can Purified Omega-3 Polyunsaturated Fatty Acids Supplementation Act Blood Pressure Levels in Untreated Normal-High Blood Pressure Subjects with Hypertriglyceridemia?

    AUTHORS: Maria Leonarda De Rosa

    KEYWORDS: Omega-3PUFAs; Blood Pressure; Hypertriglyceridemia

    JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.2, April 25, 2012

    ABSTRACT: Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but significant decrease in blood pressure (BP) level. In fact, omega-3 PUFAs exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion, partly competing with omega-6 PUFAs for common metabolic enzymes and thereby decreasing the production of vasoconstrictor rather than vasodilator and anti-inflammatory eicosanoids. PUFAs also reduce angiotensin-converting enzyme (ACE) activity, angiotensin II formation. We retrospectively evaluated the long-term effect of a omega-3 PUFAs supplementation on the blood pressure level of 91 hypertriglyceridemic subjects with untreated normal-high blood pressure that were prescribed a 3 grams omega-3 PUFAs supplementation in order to improve their plasma lipid pattern. After 24 months of treatment, systolic blood pressure (SBP) meanly decreased by 2.6 +/- 2.5 mmHg (p = 0.001) and diastolic blood pressure (DBP) by 1.4 +/- 3.1 mmHg (p